During brain development and blood-brain barrier (BBB) differentiation the expression of P-glycoprotein (P-gp) may complement the protective function of the placental barrier against xenobiotic substances. To establish an immunohistochemical procedure for Pgp detection, different anti-P-gp monoclonal antibodies were first tested on a fibrosarcoma cell line and colonic carcinoma tissue. The protocol was then tested on adult human brains as a BBB-P-gp tissue-specific control and for double labeling with anti-P-gp and the astroglia marker glial fibrillary acidic protein (GFAP). The protocol was then used to analyze the expression and localization of P-gp in human fetuses during cerebral cortex formation. At the earliest examined stage, 12 weeks of gestation (wg), P-gp was detectable as diffuse cytoplasmic labeling of the endothelial cells lining the primary cortex microvessels. At 18 wg, a punctate P-gp staining pattern was detected on cortex and subcortical vessels and on their side branches. At 22 wg, P-gp staining was linear and concentrated on endothelial cell membranes. In all examined ages, GFAP-positive radial glial cells and astrocytes did not stain for Pgp, even at their perivascular processes, whereas faint P-gp labeling was seen on vimentin-reactive radial glia at the earliest examined fetal age. At midgestation, P-gp colocalized with caveolin-pY14 on the abluminal endothelial cell membrane. These results demonstrate that P-gp is expressed early during human cerebral cortical microvessel development, and suggest that at midgestation there may be efflux activity that is regulated by interactions with the caveolar endothelial cell compartment.
INTRODUCTION
P-glycoprotein (P-gp, MDR1; gene symbol ABCB1), belongs to the ABC (ATP-binding-cassette) family of transporters and is an efflux pump that was originally found to be expressed in multidrug resistance (MDR) cancer cells (1Y4). Together with other members of the same family, P-gp protects cells against excitotoxic compounds such as chemotherapeutic, anti-epileptic drugs, and glucocorticoids (5, 6) . In normal conditions P-gp is present at several tissue interfaces (7) including the placental barrier, where it can reduce passage of xenobiotics into the fetal compartment (8Y10), and the blood-brain barrier (BBB), where P-gp prevents the passage of drugs and toxins from blood into the brain (11Y13).
From the second half of the embryonic period and throughout fetal life up until birth, the fetus exchanges respiratory gases, nutrients, and catabolic molecules via the placenta, a multifunctional organ. The placenta is not only a pulmonary-feeding filter but also secretes bioactive compounds, supplies maternal antibodies to the fetus, and prevents infective agents and xenobiotics from entering the fetal blood. These protective functions are achieved by a series of efflux pumps, P-glycoprotein, MRP1, MRP2, MRP5, and BCRP/ABCG2, which are localized at the syncytiotrophoblast epithelial lining of the placenta villi (10) . In recent years, the demonstration of a relevant role of P-gp in drug distribution at the maternal-fetal interface and pioneering studies on P-gp substrates, inhibitors (chemosensitizers), and modulators have provided consistent contributions to the field and have drawn increasing attention to the mechanisms of fetal vulnerability and protection (9, 14Y16) .
The efficiency of the placental barrier may be reinforced, as a second line of defense, by fetal organspecific barriers such as the BBB. In adult brain capillaries, the BBB is a Bsandwich-like[ neurovascular unit composed of microvascular endothelial cells on the inside, pericytes embedded in the vascular basement membrane in the middle, astrocytic endfeet facing the juxtavascular neuropil at the outside border (17) . Evidence of morphological features and an early barrier activity against Fphysiological_ molecules has been described in mammalian fetuses and newborns (18Y20). Our previous investigations on human cerebral cortex microvessels support the concept that in humans some BBB function may start early during fetal development because the BBB-specific glucose transporter, Glut-1, and the tight junction molecules, occludin and claudin-5, are expressed early and positioned at the endothelial cell membranes; a barrier to albumin, a permeability endogenous tracer, is already present at 12 weeks of gestation (wg) (21, 22) . P-gp is reported to be one of the earliest molecules to identify the BBB endothelial phenotype in mouse embryos at mRNA and protein level; in human fetuses it has been demonstrated by immunohistochemistry (IHC) in a subset of CNS microvessels (23, 24) where it is suggested to be involved in BBB differentiation and fetal brain protection (25, 26) . Nevertheless, few data are available on P-gp expression, its cellular and subcellular localization, and on its transport efficiency during human brain development, particularly cerebral cortex formation and vascularization.
In the present study IHC and laser confocal microscopy were used to analyze the expression, cellular localization, and activity/regulation of P-gp in human developing cerebral cortex, a sensitive site potentially exposed, during neurohistogenesis to detrimental effects of teratogenic substances, environmental agents and pharmaceuticals. Because it has recently been demonstrated that discrepancies between IHC detection of P-gp in normal and pathological brain tissues could be attributed to technical factors (27), we initially tested 4 different anti-human P-gp mouse monoclonal antibodies (mAbs) on differently processed human control samples, cultured fibrosarcoma cells, colonic carcinoma tissue, and adult brain to develop a suitable IHC procedure for the analysis of P-gp in the developing fetal brain. The selected antibody and IHC protocol were then used in single and double immunolabeling of P-gp, the astroglia marker glial fibrillary acidic protein (GFAP) and the glial/endothelial cytoskeletal protein vimentin. Double immunolabeling was also carried out with P-gp and the regulatory integral membrane protein of the caveolar cell compartment caveolin-1 in its phosphorylated (Tyr-14) form (caveolin-pY14).
MATERIALS AND METHODS

Immunohistochemistry
P-gp Immunolabeling of HT 1080 Cultured Cells and Colon Carcinoma Tissue
The following 4 anti-human P-gp mouse mAb clones, MRK16, C219, C494, and JSB-1 were used (Table) . As positive IHC controls, the human fibrosarcoma cell line, HT 1080, and frozen sections from human colonic carcinoma specimens were used. The cells were fixed in 4% paraformaldehyde for 1 hour at room temperature (RT) in phosphate buffered saline (PBS, pH 7.4), then the cells adherent to their growth-coverslip were incubated as follows: 1) blocking buffer (BB; PBS, 1% bovine serum albumin, 2% fetal calf serum) for 30 minutes at RT; 2) 0.5% Triton-X-100 in PBS for 10 min at RT; 3) each of the selected primary Abs (according to scaled dilutions from 1:10 to 1:100 in BB) for 40 minutes at RT; and 4) fluorophore-conjugated goat anti-mouse IgG (diluted 1:200 in BB; Alexa Fluor 488, Invitrogen, Paisley, UK) for 40 minutes at RT. Cells were counterstained with TOPRO-3 (diluted 1:10K in PBS; Invitrogen), used as third wash after conjugated, finally mounted on glass slides with Vectashield (Vector Laboratories, Burlingame, CA) and sealed with nail varnish. Frozen sections from 4 different samples of colonic carcinoma were fixed in 4% paraformaldehyde for 20 minutes and then submitted to the same staining protocol. We observed that clones MRK16 and C494 gave a strong signal on both cultured cells and frozen tissue (the results on HT 1080 cells are illustrated in Figure 1 and summarized in the Table) . In accordance with these results the antibody denoted C494 was extensively used throughout the study on human brain samples.
P-gp Immunolabeling of Adult Human Brain
Adult human brain tissue is known to express Pglycoprotein at the BBB microvessels and was used as a Invitrogen) added to the final wash. The sections were then transferred onto Vectabond treated slides (Vector Laboratories), carefully drained, coverslipped in Vectashield mounting medium (Vector Laboratories), and sealed with nail varnish. Negative control sections were prepared by: 1) omitting one of the primary antibodies, 2) pre-adsorbing the primary antibodies with an excess (20 nM) of the pure antigen when available, and 3) mismatching the secondary antibodies. In all cases, the results of these negative controls confirmed the specificity of the antibody staining. Sections with areas free from reactive gliosis were considered as normal tissue. All procedures were conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Canton Zurich. Informed written consent was obtained from the patients.
P-gp Immunolabeling of Fetal Human Brain
Autopsy specimens of telencephalon were collected from 6 fetuses spontaneously aborted due to preterm rupture of the placental membranes at 12, 18, and 22 wg (2 for each of the examined ages), with no history of neurological pathologies. The sampling and handling of human specimens conformed to the ethical rules of the Department of Pathology, Medical School, University of Bari, Italy, and approval was gained from the local Ethics Committee of the National Health System in compliance with the principles stated in the Declaration of Helsinki. The fetal age was estimated on the basis of the crown-rump length and/or pregnancy records (counting from the last menstrual period). At autopsy, the selected fetuses did not reveal macroscopic structural abnormalities and/or malformations of the central nervous system (Fig. 1A) . Coronal slices (= 3-mm thick) of the dorso-lateral wall of the telencephalic vesicles (future neocortex) were dissected, halved, and fixed for 3 hours at 4-C by immersion in 2% paraformaldehyde plus 0.2% glutaraldehyde solution. Specimens were then washed in phosphate buffered saline (PBS, pH 7.6) and stored at 4-C. Halves of the telencephalon samples were embedded in paraffin and serially sectioned for conventional histological analysis with either hematoxylin and eosin staining or toluidine blue staining, and absence of microscopic malformations was ascertained (Fig. 1BYD ). Twenty-Km vibratome sections obtained from the remaining tissue samples were collected in PBS and stored at 4-C. The previously described IHC method optimized on adult human brain was applied to the study of fetal brain tissue for the detection of P-gp with mAb C494 (diluted 1:10 in BB) in single and double immunolabelings with anti-GFAP (diluted 1:1 in BB; ImmunoStar) and with a rabbit antivimentin antibody (diluted 1:200 in BB; Chemicon International, Temecula, CA). On sections from 22 wg fetuses, double immunoreactions were also carried out with P-gp C494 and a phospho-specific (Tyr-14) mouse mAb antiCaveolin-1 (caveolin-pY14, diluted 1:50 in BB; BD Biosciences, San Jose, CA); the primary antibodies were detected according to the already described staining protocol, except for the secondary antibodies, which were an isotype-specific fluorescein-conjugated goat anti-mouse IgG 2a -FITC (diluted 1:100 in BB; Santa Cruz Biotechnology, Santa Cruz, CA) and the Alexa Fluor 555 goat antimouse IgG 1 (diluted 1:200 in BB; Invitrogen) for P-gp and caveolin-pY14 detection, respectively.
Laser Scanning Confocal Microscopy
Confocal analysis was carried out using the confocal laser-scanning microscope TCS SP2 (Leica, Wetzlar, Germany) with a 63Â objective lens and either Â1 or Â2 zoom factors. Analyses of double immunolabeled sections were always carried out according to a sequential scanning procedure. Confocal images were taken and analyzed at 350-nm intervals through the z-axis of the section. Individual optical planes and stacks of serial optical sections (projection images) were digitally recorded as single channel and overlay (merged image) and finally stored as TIFF files using Adobe Photoshop software (Adobe System, San Jose, CA). Representative images from all the examined samples were chosen for figure editing.
Western Blot Analysis
At autopsy, discrete areas of the dorso-lateral wall of the telencephalic vesicles from fetuses at 22 wg were dissected and frozen at j80-C. The samples were homogenized in a glass potter homogenator with RIPA buffer containing 1% Igepal CA-630, 0.5% Sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail. The homogenate was centrifuged at 1000 rpm for 15 minutes at 4-C. The supernatant is referred to as the total protein content. Protein concentrations were measured using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA). Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Invitrogen, Carlsbad, CA). After immunoblotting with anti-human P-gp mouse mAb clone C494 (diluted 1:500; Signet Laboratories, Dedham, MA) and anti-A-actin mouse mAb (diluted 1:2000; Santa Cruz Biotechnology) as a loading control, immune complexes were visualized by incubation with the appropriate horseradish peroxidase-conjugated antibody and the ECL detection system (Amersham, Piscataway, NJ). A human breast cancer cell line (MDA-MB-231) and human primary osteoblasts were used as positive and negative controls, respectively, and submitted to the same immunoblotting protocol and analysis.
RESULTS
HT 1080 Cultured Cells and Colon Carcinoma Tissue
The 4 monoclonal anti-P-gp antibodies, clones MRK16, C219, C494 and JSB-1, show differences in their staining pattern and immunoreactivity levels when tested on both fibrosarcoma cell line HT 1080 and colonic carcinoma. The signal obtained with MRK16 on fibrosarcoma cells is strong, it appears both diffuse in the cell cytoplasm and concentrated at its periphery; with C219 the staining is very weak and prevails within the cytoplasm; C494 gives a very strong signal, intense and highly concentrated at the cell membranes; finally, JSB-1 staining is weak compared with MRK16 and C494 ( Fig. 2; Table) . On frozen sections from human colon carcinoma tissue the strongest signal is obtained with clone C494, P-gp reactivity being also intense with MRK16, whereas it appears weak and very weak with C219 and JSB-1, respectively (Table) . In conclusion, the mAb clone C494 showed the best immuno signal on both tumor cells and carcinoma sections; therefore, this antibody was used subsequently in our study with the optimized IHC protocol.
Adult Human Brain
Sections from adult human parahippocampal gyrus were used as an organ-specific control for BBB-P-gp expression in association with the astroglia cytoskeletal marker GFAP. Reactive gliosis represents a consistent finding in temporal lobe tissue from mesial temporal lobe epilepsy patients, and immunolabeling with GFAP allows virtually gliosis-free areas to be recognized. These are mostly located in the grey matter outermost layers, whereas in the deeper layers and white matter areas, gliosis is evident and characterized by intensely GFAP-stained, reactive and hypertrophic astrocytes. In the identified silent cortex regions, P-gp appears expressed by endothelial cells, and by smooth muscle cells and pericytes of small penetrating arterioles and capillaries, respectively (Fig. 3AYI) . Analysis by double staining with GFAP reveals that both parenchymal and perivascular astrocytes are P-gp-negative, their body, processes and perivascular endfeet appearing only stained by GFAP (Fig. 3AYI) . The P-gp/GFAP projection images have also been analyzed on single confocal optical planes to ascertain the absence of P-gp in perivascular astrocyte endfeet in contact with the vessel wall (data not shown). (G-I) High magnification of a transversely cut small capillary, which shows a P-gp-labeled endothelial cell (E, in G and I) and the detail of a P-gp-positive pericyte (P, in G and I), together with an almost complete, GFAP-positive glial ring (H, I; in I, E and P mark the nuclei of the GFAP-negative endothelial cell and pericyte, respectively). Scale bars = (A-F) 30 Km; (G-I) 5 Km.
Fetal Human Brain
We next assessed the expression and localization of P-gp during development of human telencephalon (future cerebral hemispheres), at 12, 18, and 22 wg, from the beginning of cerebral cortex formation, soon after pre-plate formation and vascularization, to the end of neuroblast supply to the cortex and incoming lamination (28, 29) . The telencephalon sections were first single labeled for P-gp with mAb C494 to evaluate the antigen-staining pattern in each of the examined ages (Fig. 4AYI) . Thereafter, double immunostainings were performed with GFAP and vimentin to evaluate the cellular expression of P-gp on vascular and glial compartments (Figs. 5Y7) . Finally, according to the observed developmentally regulated changes of endothelial P-gp cell distribution and staining pattern, possible signs of P-gp interaction with the caveolar compartment were analyzed at 22 wg by double labeling with Caveolin-pY14 (Fig. 8) .
In single immunolabelings carried out at 12 wg, P-gp was detectable as an intense, diffuse staining of the endothelial cytoplasm in microvessels that initially vascularize the forming neocortex (Fig. 4AYC) . Later, at 18 wg, P-gp was recognizable as a strong, punctate staining of the endothelial cells lining the elongating radial vessels that at this time form the basic scheme of the future vascular network, giving rise to side branches which also show a well detectable P-gp staining (Fig. 4DYF) . At 22 wg, the endothelial P-gp immuno signal changes from the cytoplasmic, punctate pattern to a linear and continuous labeling on both the cortex and subcortical microvessels. The P-gp linear pattern corresponds to the endothelial cell membranes and is clearly recognizable in long vessel profiles and on single endothelial cells (Fig. 4GYI) . At this time P-gp-positive pericyte-like cells adherent to the microvessel wall are also recognizable (Fig. 4H, inset and I) .
Confocal analysis of P-gp/GFAP double-labeled sections, at 12 and 18 wg, confirms that P-gp is restricted to the vascular wall with an intense, cytoplasmic endothelial staining, and that GFAP-positive astroglia do not stain for P-gp either in the neuropil or perivascular endfeet (Fig. 5AYF) . At midgestation, GFAP typically marks astrocytes, their radial glia precursors, and a well-developed perivascular glial sheet. These cells and structures do not show detectable P-gp staining, which appears restricted to endothelial cells and pericytes of cortical and subcortical microvessels (Fig. 6AYL) . In the cortex, there is intense, linear P-gp staining of endothelial cells identifiable between regular rows of packed neuroblasts, which are in contact with GFAP-positive radial glial fibers (Fig. 6AYC) . Within the subcortical layers, P-gp-labeled microvessels pass through a parallel arrangement of radial, GFAP-positive astroglia processes and are almost completely enveloped by the GFAP-positive/P-gp-negative endfeet of young astrocytes (Fig. 6DYL ). Differences in P-gp cellular expression and distribution at this time were observed analyzing high magnifications of the vascular fields. Extensive tracts of the microvessels are intensely P-gp stained and the transporter is localized either on the endothelial luminal side (Fig. 6DYF) or on both the luminal and abluminal endothelial fronts (Fig. 6IYL) . Very low or undetectable levels of the transporter have also been observed on single endothelial cells, as short negative tracts of the vessel profiles (Fig. 6GYI, L) .
Because of strong reactivity of both early radial glia cells and endothelial cells for the cytoskeletal protein vimentin, a double P-gp/vimentin immunolabeling was also carried out at the different fetal ages. At 12 wg, early P-gp reactivity of penetrating microvessels also showed its colocalization with endothelial vimentin reactivity (Fig.  7AYC) . As expected, vimentin was detected in many radial glia fibers, together with a rare and a very low reactivity for P-gp (Fig. 7AYC) . At both 18 and 22 wg, vimentin appears restricted to the endothelial cells of the telencephalic microvessels, where it extensively colocalizes with P-gp reactivity (Fig. 7DYI) .
No differences in P-gp expression were detected between cerebral cortex microvessels and microvessels located within the cortex boundary regions, the outermost marginal zone and the subjacent subplate zone (Figs. 4Y7) .
The findings of heterogeneity of P-gp detection in endothelial cells and observed differences in the subcellular P-gp distribution suggested possible, indirect evidence of corresponding endothelial cell functions. This issue was further analyzed by performing double immunolabeling with P-gp and the phosphorylated form of caveolin-1 (caveolin-pY14). At 22 wg, on P-gp/Caveolin-pY14-stained sections, all the cortex microvessels express constant and well detectable levels of Caveolin-pY14, which appears to prevail on the abluminal side of the endothelial cells, whereas P-gp is concentrated on their luminal endothelium (Fig. 8AYJ) . When the transporter is present on both the luminal and abluminal endothelial membranes it extensively colocalizes with Caveolin-pY14 at the abluminal site (Fig.  8C, D, HYJ) . An immunoblot analysis with anti-human P-gp mouse mAb clone C494 carried out on brain tissue extracts from 22 wg fetuses confirmed the presence of P-gp in the human telencephalic vesicles, showing a detectable single band of expected size corresponding to the plasma membrane associated 170 to 180 kD glycoprotein. A predicted stronger (A-C) P-gp-labeled endothelial cells of a microvessel slipping down through the cortex surrounded by a GFAP-labeled glial scaffolding. (D-F) P-gp-positive, subcortical microvessels surrounded by GFAP-labeled radial glia processes and perivascular astrocytes; P-gp prevails on the luminal cell membrane of some endothelial cells (D, inset; F, inset) and is absent in the astrocyte perivascular endfeet (E, inset; F, inset); (G-L) Note P-gp-negative tracts of the endothelial lining (G, I; L, enlargement of the marked area in I, arrowhead) and portions of the vessel wall where the luminal and abluminal localization of the transporter is recognizable (L, arrow); a GFAP-labeled astrocyte is anchored to a P-gp-positive microvessel (J; K, enlargement of the marked area in J), note in K a site of endothelial P-gp luminal and abluminal localization (arrowhead). Scale bars = (A-I) 50 Km; (inset in D-F, K) 10 Km; (J) 30 Km; (L) 15 Km. signal was detected for the human breast cancer cell line (MDA-MB-231), whereas the glycoprotein was virtually absent in the examined human primary osteoblasts (Fig. 9) .
DISCUSSION
Previous studies have suggested that technical difficulties can explain conflicting data on the expression pattern and cellular localization of multidrug transporters (27, 30, 31) . In our study, among the 4 different anti-P-gp mAb clones tested, the clone denoted C494 gave the best results, yielding reliable and sensitive P-gp labeling on fibrosarcoma cells and colonic tumor tissues, as well as on adult brain tissue. In the latter, according to previous studies carried out at protein and mRNA level (11, 12, 31Y33) , P-gp is primarily expressed by endothelial cells.
Previous studies have demonstrated that expression of the Mdr1a/3 gene starts in endothelial cells at a very early stage of mouse neural tube development and that the Mdr1a/ 3 transcript increases with postnatal maturation of mouse BBB microvessels (23, 34) . In human fetuses, a faint P-gp staining has been demonstrated by IHC at 8 wg in different brain regions that progressively increased during development (24) . Our present results confirm these data and demonstrate a strong expression of P-gp in endothelial cells lining the primary cortex microvessels at 12 wg, the elongating radial vessels and their first collaterals at 18 weeks, the cortical and subcortical microvessels at midgestation. At this time, the punctate, P-gp staining changes to a linear and continuous labeling that can be identified on the luminal and abluminal endothelial membranes. In the developing human brain, therefore, early P-gp-BBB expression and functional efficiency may, along with the extra-fetal placental system of protection, play an important role in the mechanisms limiting access to the brain of toxic xenobiotics, including potentially teratogenic substances.
The distribution of P-gp within the neurovascular unit is controversial (31) . Recent studies have shown localization of several members of the efflux transporter family (ABCBC, ABCC, BCRP/ABCG2) at the luminal side of brain capillary endothelial cells and some of them (MRP4 and MRP5) were also detected in astrocytes (35) . Our results demonstrate that the expression of P-gp in endothelial cells is a common feature in human adult and fetal microvessels, with a minor contribution in pericyte-like cells, whereas it is absent in both GFAP-positive parenchymal and perivascular astrocytes. On the contrary, a few vimentin-positive radial glia fibers also show a very low and sparse reactivity for Pgp, this observation being limited to the earliest examined developmental stages. This reactivity is interpreted as a remnant of the P-gp expression in vimentin-positive neuroepithelial precursors on the basis of recent observations on P-gp expression in developing human telencephalon (personal communication; (36) ).
Although it is well known that early astroglia and microvessel maturation take place in the subplate zone (37) and that this prominent, transient layer actively integrates and processes synaptic inputs from cortical and subcortical areas (38Y40), our results do not indicate differences in the level of P-gp expression in this layer compared with the developing neocortex area; these observations confirm the transporter as one of the earliest markers of the BBB FIGURE 8. Fetal human brain tissue double labeled for P-gp and caveolin-pY14 at 22 weeks of gestation. (A-C) Some discontinuity of the P-gp endothelial labeling is observed on a small venule (A), whereas the caveolin-pY14 endothelial staining is uninterrupted (B); the different distribution of the 2 markers is better demonstrated on the merged image (C) and on the enlarged pictures of 2 endothelial cells marked in C by E 1 and E 2 : in E 1 (D) P-gp colocalizes with caveolin-pY14 only on the endothelial abluminal front; in E2 (E) P-gp is absent and caveolin-pY14 mainly stains the abluminal endothelial side. (F-H) A microvessel continuously labeled for both P-gp (F) and caveolin-pY14 (G); they prevail on the luminal and abluminal endothelial front, respectively, as better shown on the merged image (H) and on the enlarged pictures (I, J) of 2 endothelial cells marked in H by E 3 and E 4 ; both E 3 and E 4 show P-gp concentrated on the luminal side and P-gp/caveolin-pY14 colocalized to the opposite cell front. Scale bars = (A-C, F-H) 50 Km; (D, E, I, J) 10 Km.
endothelial cell phenotype. With regard to its cellular and subcellular localization, P-gp is extensively present on both luminal and abluminal endothelial cell membranes, but it can be absent on the abluminal front for short vascular tracts and, on some microvessels, P-gp-negative endothelial cells have also been detected. These differences in P-gp expression and localization support the idea of a functional BBB heterogeneity of different vascular segments (41) , and also suggest a heterogeneous nature of the endothelial cells themselves. Stewart et al have suggested an organ-specific role played by P-gp according to its different luminal and/or abluminal localization in endothelial cells (42) . A luminal Pgp location indicates inhibited passage of diffusible substances from the blood to the tissue or, alternatively, the extrusion of substances from the tissue into the blood. A luminal and abluminal P-gp location supports its role in excluding substances from the endothelial cells themselves, similarly to cancer cell efflux transport. In fetal brain microvessels, both these mechanisms may occur at the same time due to the co-existence of microvessels characterized by either luminal or luminal and abluminal endothelial P-gp distribution.
Biochemical and immunohistochemical studies in vitro and in vivo have demonstrated that interactions between P-gp and caveolin-1 take place within the caveolar compartment of brain endothelial cells (32, 43, 44) . Moreover, it has recently been shown that the controversial data on the negative and/or positive caveolin-1 modulation of Pgp activity can be reconciled because of in vitro and in vivo demonstrations that caveolin-1 tyrosine phosphorylation determines P-gp inhibition and accumulation of specific substrates in BBB endothelial cells (45, 46) . In human fetal brain microvessels, the highest levels of P-gp/caveolin-pY14 colocalization have been observed on the abluminal endothelial cell front whereas a caveolin-pY14-free P-gp is concentrated on the endothelial luminal side. These observations demonstrate that P-gp may function by extruding diffusible substances from the endothelial cells into the blood, whereas its activity on the opposite side is under the control of the caveolin-1 phosphorylated form.
Recently, studies on placental pharmacokinetics in vivo performed by dually perfused rat and human placentas have definitely demonstrated the involvement of MDR transporters in materno-fetal and feto-maternal xenobiotic clearance. In particular, data obtained from the study of Pgp-deficient mice indicate the involvement of placental syncytiotrophoblast P-gp in limiting the access to the fetal blood circulation of potentially toxic substances, including therapeutic compounds (9, 10, 16, 47) . Unlike in rodent placenta, where an increase of P-gp was observed towards term (14) , in human placenta the P-gp expression decreases with advancing gestational age (48) , parallel with the progressive increase of P-gp-BBB expression (24, 34) . These species-specific differences support our hypothesis of an earlier functional efficiency of P-gp in human versus rodent brain. Moreover, the fetal origin of the syncytiotrophoblast layer on the placental villi supports the idea of an active fetal Fbarrier system_ working as a second line of defense, capable of cooperating with the placental barrier to limit the access of potentially harmful and/or teratogenic substances to sensitive developing organs.
In conclusion, the present results document a dynamic state of P-gp in human fetal brain, consistent with its specific function in protecting the unique microenvironment of the developing human cerebral cortex.
